
November 19, 2017 - By Dolores Ford
Among 14 analysts covering Prothena Corp (NASDAQ:PRTA), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Prothena Corp had 25 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Buy” rating by SunTrust given on Wednesday, December 21. The company was maintained on Wednesday, November 8 by Cantor Fitzgerald. BTIG Research maintained the stock with “Buy” rating in Friday, September 29 report. RBC Capital Markets maintained the shares of PRTA in report on Thursday, November 19 with “Outperform” rating. The rating was initiated by Suntrust Robinson with “Buy” on Wednesday, December 21. Credit Suisse initiated Prothena Corporation PLC (NASDAQ:PRTA) on Thursday, January 21 with “Outperform” rating. Barclays Capital initiated Prothena Corporation PLC (NASDAQ:PRTA) rating on Friday, May 13. Barclays Capital has “Overweight” rating and $60 target. The company was maintained on Tuesday, August 4 by Wedbush. The stock of Prothena Corporation PLC (NASDAQ:PRTA) has “Buy” rating given on Thursday, November 3 by Deutsche Bank. As per Friday, February 19, the company rating was maintained by Wedbush. See Prothena Corporation PLC (NASDAQ:PRTA) latest ratings:08/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $80.0 Maintain02/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $87.0 Maintain23/10/2017 Broker: Deutsche Bank Rating: Buy New Target: $73.0 Maintain29/09/2017 Broker: Deutsche Bank Rating: Buy 29/09/2017 Broker: BTIG Research Rating: Buy Old Target: $80 New Target: $77 Maintain28/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $79.0 Maintain15/09/2017 Broker: RBC Capital Markets Rating: Outperform New Target: $87 Initiates Coverage On17/08/2017 Broker: Evercore Rating: Outperform New Target: $83 Initiates Coverage On11/07/2017 Broker: Jefferies Rating: Buy New Target: $100 Initiates Coverage On06/07/2017 Broker: Oppenheimer Rating: Buy New Target: $70.0000 InitiateING Groep NV (ADR) (ING) formed double top with $19.32 target or 7.00% above today’s $18.06 share price. ING Groep NV (ADR) (ING) has $70.00B valuation. The stock decreased 0.11% or $0.02 on November 17, reaching $18.06. About 3.14M shares traded or 54.68% up from the average. ING Groep NV (ADR) (NYSE:ING) has risen 45.69% since November 19, 2016 and is uptrending. It has outperformed by 28.99% the S&P500.Among 9 analysts covering ING Groep N.V. (NYSE:ING), 5 have Buy rating, 1 Sell and 3 Hold. Therefore 56% are positive. ING Groep N.V. had 10 analyst reports since August 27, 2015 according to SRatingsIntel. On Tuesday, January 17 the stock rating was downgraded by Goldman Sachs to “Neutral”. The firm earned “Buy” rating on Tuesday, June 20 by Deutsche Bank. Deutsche Bank upgraded the shares of ING in report on Thursday, August 27 to “Buy” rating. The firm has “Hold” rating by HSBC given on Wednesday, May 31. The firm has “Buy” rating by Natixis given on Friday, October 9. RBC Capital Markets upgraded the shares of ING in report on Friday, September 23 to “Outperform” rating. The rating was upgraded by Kepler Cheuvreux on Friday, February 5 to “Buy”. On Thursday, March 31 the stock rating was downgraded by Morgan Stanley to “Underweight”. The stock of ING Groep NV (ADR) (NYSE:ING) has “Hold” rating given on Wednesday, December 7 by Independent Research.Prothena Corporation Public Limited Company is a global biotechnology company. The company has market cap of $1.99 billion. The Firm is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It currently has negative earnings. The Company’s clinical pipeline of antibody product candidates targets a range of indications, including Amyloid Light-chain amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.


var data = "63557954";
document.write('<ins class="adsbygoogle" style="background-color:transparent; display:inline-block;width:300px;height:600px;" data-ad-client="ca-pub-16900'+data+'675" data-ad-slot="8925061741"></ins>')

(adsbygoogle = window.adsbygoogle || []).push({});
(adsbygoogle = window.adsbygoogle || []).push({});